Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | Neuroscientific Biopharmaceuticals Ltd (NSB.ASX) |
|---|---|
| Release Time | 28 Jul 2026, 10:02 a.m. |
| Price Sensitive | Yes |
Neuroscientific Biopharmaceuticals Ltd. Quarterly Activities Report
- Successful treatment of five patients with fistulising Crohn's Disease using StemSmart™ technology
- Positive clinical trial planning for fistulising Crohn's Disease in Australia and refractory Crohn's Disease in Australia and the US
- Technology transfer for StemSmart™ manufacturing to Q-Gen Cell Therapeutics progressing as planned
- Cash balance of $4.6M as at 30 June 2026
NeuroScientific Biopharmaceuticals Ltd. (ASX:NSB) has released its Quarterly Activities Report for the period ended 30 June 2026, highlighting several key developments. Five patients with fistulising Crohn's disease treated under the TGA's Special Access Scheme using StemSmart™ technology showed promising results, with four patients achieving a clinical response. The company is now planning Phase 2 clinical trials for fistulising Crohn's disease in Australia and refractory Crohn's disease in Australia and the US. Additionally, the technology transfer of StemSmart™ manufacturing to Q-Gen Cell Therapeutics is progressing as planned, with the full transfer program expected to complete in the second half of 2026. The company reported a cash balance of $4.6 million as of 30 June 2026, providing sufficient funding for planned clinical development and manufacturing activities.
NeuroScientific Biopharmaceuticals Ltd. plans to complete the StemSmart™ technology transfer to Q-Gen Cell Therapeutics and finalize clinical trial preparations for Phase 2 trials in the second half of 2026.